SILVER SPRING, Md. (WTVO) – AstraZeneca reportedly asked the FDA to authorize an antibody treatment for emergency use to prevent COVID-19.
The company said that the drug might help to protect people whose immune systems do not respond enough to the vaccines. Late-stage human trials showed that the treatment reduced the risk of developing symptomatic COVID-19 by 77%.
More than 75% of the participants had suppressed immune systems, among other conditions, that made them more susceptible to severe disease.
AstraZeneca claimed that the drug would be the first, long-acting antibody combination to receive an emergency use authorization to stave off the virus.